Drug Profile
Research programme: antibody therapeutics - Adimab/Human Genome Sciences
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Adimab; Human Genome Sciences
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Undefined in USA (Parenteral)
- 03 Aug 2012 Human Genome Sciences has been acquired by GlaxoSmithKline
- 30 Aug 2011 Early research is ongoing in USA